All In Biotech

Drug Trial Radar · NCT07751341

A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

A Randomized, Controlled, Open-label, Multicenter Phase II Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Sep 7, 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter, randomized, phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839(sc) as monotherapy or in combination with chemotherapy plus adebelimab in patients with advanced esophageal squamous cell carcinoma (ESCC).

Conditions

  • Advanced Esophageal Squamous Cell Carcinoma

Interventions

  • SHR-9839(sc) for InjectionDrug

    SHR-9839(sc) for Injection,dose level 1

  • SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin InjecionDrug

    Safety run-in Stage: SHR-9839(sc) for Injection ,dose level 1 or lower dose、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion; Dose extension Stage: SHR-9839(sc) for Injection,dose according to Safety run-in Stage、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion or Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR:Objective Response RateTime frame: First administration to end of treatment visit about 1year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital Of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.